3559 results for «278»
3559 results
TAVI cases: the unexpected and the unseen
11 Sep 2025 – From PCR Rio Valves 2025
Explore this session to uncover complex and unexpected challenges encountered during TAVI procedures. Cases include incidental findings such as aortic valve annulus pseudoaneurysm, double coronary artery perforation in severe aortic stenosis, and unique scenarios involving self-expanding valve implantation and transseptal access. Learn strategies for managing bioprosthesis...
Tricuspid TEER intraprocedural guidance
12 Sep 2025 – From PCR Rio Valves 2025
Master the intraprocedural guidance essential for successful Tricuspid Transcatheter Edge-to-Edge Repair (TEER). This session provides comprehensive insights into pre-procedural analysis, gap measurement techniques, and step-by-step intraprocedural monitoring with expert tips and tricks.
Mitral TEER intraprocedural guidance
11 Sep 2025 – From PCR Rio Valves 2025
This session offers a detailed exploration of mitral TEER intraprocedural guidance through case-based learning. It highlights step-by-step techniques, including post-processing and key questions interventionalists face regarding residual regurgitation, clip insertion, and evaluating final procedural outcomes.
Minimalist approach to tricuspid valve therapy
11 Sep 2025 – From PCR Rio Valves 2025
This session highlights the minimalist approach to tricuspid valve therapy with TricValve implantation, a contrast-free, minimally invasive procedure guided by transthoracic echo and minimal fluoroscopy. Clinical evidence shows reduced hospitalisations, improved quality of life, and encouraging mid-term outcomes, including smaller right heart chamber dimensions and reduced...
Transcatheter tricuspid valve replacement - Where are we in Latin America?
12 Sep 2025 – From PCR Rio Valves 2025
Stay abreast of the latest advances in transcatheter tricuspid valve replacement (TTVR) across Latin America. This session highlights orthotopic implant technologies, patient selection criteria, early clinical outcomes, and discusses future perspectives including training, technology access, and regional clinical impact.
Extreme TAVI: bicuspid valves, emergency TAVI, dissections and more
12 Sep 2025 – From PCR Rio Valves 2025
Explore extreme and complex TAVI cases that push procedural limits, including urgent interventions, bicuspid valve sizing, valve-in-valve strategies, and rare complications such as type A dissection and late coronary occlusion. This session shares valuable clinical experiences and lessons from challenging scenarios.
Innovation session: new techniques and devices in Latin America
11 Sep 2025 – From PCR Rio Valves 2025
Join this innovation-focused session highlighting new structural heart devices and techniques emerging from Latin America. Review real-world cases including mechanical valve re-intervention, TMVR, novel mitral TEER devices, and first clinical experiences with a new self-expandable transcatheter aortic valve in small annuli. Gain valuable procedural and clinical...
Tricuspid and mitral: fine tuning diagnosis and results in transcatheter valve management
11 Sep 2025 – From PCR Rio Valves 2025
This session focuses on refining diagnosis and treatment outcomes in transcatheter management of tricuspid and mitral valves. Topics include assessment of pulmonary artery pressure changes post-MitraClip, 3D echocardiographic evaluation of tricuspid regurgitation severity, quantitative improvements in imaging, and insights from single-centre experiences. Additional discussions cover bicaval...
Tricuspid valve - Present and future perspectives: a critical appraisal
12 Sep 2025 – From PCR Rio Valves 2025
Explore the cutting-edge developments and practical insights in tricuspid valve interventions in this comprehensive session. Learn about the current status and patient selection for orthotopic valve implantation, gain expert guidance on intraprocedural monitoring with step-by-step tips, and understand the critical information required for pre, intra, and...
Structural heart: demanding anatomies, difficult situations and unusual strategies
12 Sep 2025 – From PCR Rio Valves 2025
Navigate complex structural heart interventions through this session focusing on challenging anatomies and innovative procedural strategies. Topics include orthotopic tricuspid valve replacement amidst anatomical and physiological complexities, percutaneous closure of Valsalva sinus fistula, extreme TAVI approaches for pure aortic regurgitation, management of mitral paravalvular leaks with...
The complexity of transcatheter tricuspid valve interventions
11 Sep 2025 – From PCR Rio Valves 2025
Understand the complexities of transcatheter tricuspid valve interventions through diverse case studies addressing challenging clinical scenarios. Learn about therapeutic alternatives including TEER with pacemaker leads, imaging challenges with ICE, transcatheter tricuspid valve replacement with Evoque and LuxValve devices, and straightforward options like TricValve. Gain perspective on...
Advanced TAVI: techniques, timing, and problem-solving
12 Sep 2025 – From PCR Rio Valves 2025
Advance your knowledge in TAVI with this session addressing sophisticated techniques, procedural timing, and problem-solving in complex cases. Explore TAVI applications in rare quadricuspid valve anatomy with pure aortic insufficiency, strategic decision-making between TAVI and PCI, and innovative solutions for managing aortic stenosis in patients with...
Management of hostile access for TAVI
11 Sep 2025 – From PCR Rio Valves 2025
Access challenges are among the most critical hurdles in TAVI procedures. This session explores how to identify difficult access routes using pre-procedural CT, and demonstrates practical techniques to safely overcome these obstacles. Through real-life case presentations—including challenging femoral access with a shockwave balloon, carotid access, and...
Long-term results and durability of the CoreValve transcatheter aortic bioprosthesis: outcomes beyond five years
28 Mar 2019
A study to determine the long-term outcomes of high-risk patients who underwent transcatheter aortic valve implantation with the third-generation CoreValve device, according to the 2017 EAPCI/ESC/EACTS definition of valve durability.
Authors :
Impella percutaneous ventricular assist device malrotation in social media: a call to action
20 Apr 2023
The data from this study suggest that, from a SoMe perspective, correct Impella orientation is often overlooked, and that Impella malrotation is a common issue in real-world clinical practice, potentially associated with relevant complications.
Author
Author
Author
Author
Author
30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
The impact of COVID-19 pandemic on interventional cardiologists in training
23 Oct 2020
In collaboration with EuroIntervention Journal
The authors decided to create a survey tailored for ICTs in order to assess the changes in their training. Capturing the essence of the responses may help to identify the most appropriate strategies to provide the highest standards and skills achievements in COVID-19...
Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes: The multicenter, randomized, blinded, IVUS-ACS Trial
09 Apr 2024
Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)
Author
Author
